81231 Cyp3a5 gene common variants
Also known as: CYP3A5 pharmacogenetic panel, CYP3A5 variant testing
Molecular analysis of the CYP3A5 gene to identify common pharmacogenetic variants affecting drug metabolism.
In Plain Language
medicine metabolism gene test; drug response genetic testing
Clinical Context
Used to guide dosing of CYP3A5 substrates (e.g., tacrolimus, cyclosporine) to optimize transplant rejection prevention and adverse effect avoidance.
RVU Information
CPT 81231 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Lab and pathology codes require an order from the treating provider with clinical indication. For molecular pathology and genetic testing, document the specific analytes tested and clinical rationale.
How This Code Compares
This code has a work RVU of 0.00, meaning it does not have a physician work component assigned by CMS. In the Pathology & Lab category, 94% of codes share this characteristic.
Specialties
Frequently Asked Questions
What is CPT code 81231?
CPT 81231 (Cyp3a5 gene common variants) is a Pathology & Lab code. Molecular analysis of the CYP3A5 gene to identify common pharmacogenetic variants affecting drug metabolism.
Who uses CPT code 81231?
CPT 81231 is used by Pathology, Pharmacology, Clinical Genetics. Used to guide dosing of CYP3A5 substrates (e.g., tacrolimus, cyclosporine) to optimize transplant rejection prevention and adverse effect avoidance.
When is CPT 81231 used?
Used to guide dosing of CYP3A5 substrates (e.g., tacrolimus, cyclosporine) to optimize transplant rejection prevention and adverse effect avoidance.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.